An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human), modified Process 60mg/kg in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin Deficiency

Project Details

StatusActive
Effective start/end date11/10/2131/10/24

Funding

  • IQVIA RDS Pty. Limited: A$122,641.00